Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sundström

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Neurology|October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacyJonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 6, 2023
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damageDaniel Jons, Viktor Grut, Tomas Bergström, et al.
Neurology|June 10, 2025
Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG StudyMalin Petersson, Daniel Jons, Amalia Feresiadou, et al.
European Journal of Neurology|October 16, 2020
Epstein-Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosisM Biström, D Jons, E Engdahl, et al.
Brain : a Journal of Neurology|April 17, 2024
Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesisJesse Huang, Katarina Tengvall, Izaura Bomfim Lima, et al.
Brain : a Journal of Neurology|November 6, 2023
Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosisViktor Grut, Martin Biström, Jonatan Salzer, et al.
JAMA Neurology|September 19, 2022
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical TrialFredrik Piehl, Ann Eriksson-Dufva, Anna Budzianowska, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|November 6, 2025
Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical TrialJing Wu, Ann Eriksson-Dufva, Anna Budzianowska, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Neurology|October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacyJonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 6, 2023
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damageDaniel Jons, Viktor Grut, Tomas Bergström, et al.
Neurology|June 10, 2025
Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG StudyMalin Petersson, Daniel Jons, Amalia Feresiadou, et al.
European Journal of Neurology|October 16, 2020
Epstein-Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosisM Biström, D Jons, E Engdahl, et al.
Brain : a Journal of Neurology|April 17, 2024
Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesisJesse Huang, Katarina Tengvall, Izaura Bomfim Lima, et al.
Brain : a Journal of Neurology|November 6, 2023
Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosisViktor Grut, Martin Biström, Jonatan Salzer, et al.
JAMA Neurology|September 19, 2022
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical TrialFredrik Piehl, Ann Eriksson-Dufva, Anna Budzianowska, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|November 6, 2025
Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical TrialJing Wu, Ann Eriksson-Dufva, Anna Budzianowska, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Pageof 6